Table 3.
Treatment Patterns by Sex and by Stage for Patients With Lung Cancer From UH (2005–2020) Database
| Feature | Stages 0–II |
Stages III–IV |
||||
|---|---|---|---|---|---|---|
| Male 646 (46.7%) |
Female 736 (53.3%) |
pValue | Male 1832 (50.3%) |
Female 1807 (49.7%) |
p Value | |
| Chemo, n (%)a | ||||||
| Yes | 228 (35.3) | 205 (27.9) | 0.003 | 1205 (65.8) | 1246 (69) | 0.04 |
| Surgery, n (%)a | ||||||
| Ye | 322 (49.8) | 424 (57.6) | 0.004 | 225 (12.3) | 231 (12.8) | 0.68 |
| Immunotherapy or PD-L1 inhibitors, n (%)a | ||||||
| Yes | 123 (19) | 111 (15.1) | 0.06 | 549 (30) | 565 (31.3) | 0.41 |
| Targeted therapy, n (%)a | ||||||
| Yes | 9 (1.4) | 7 (1) | 0.60 | 81 (4.4) | 99 (5.5) | 0.16 |
| Time to chemo, n (%)a | ||||||
| ≤30 d | 51 (26.3) | 51 (28) | 0.79 | 540 (57) | 507 (51.8) | 0.02 |
| >30 d | 143 (73.7) | 131 (72) | 407 (43) | 471 (48.2) | ||
| Time to immunotherapy, n (%)a | ||||||
| ≤50 d | 29 (23.8) | 22 (20) | 0.59 | 317 (57.8) | 299 (53.3) | 0.14 |
| >50 d | 93 (76.2) | 88 (80) | 231 (42.2) | 262 (46.7) | ||
| Time to surgery, n (%)a | ||||||
| ≤30 d | 102 (52.6) | 134 (53.6) | 0.90 | 61 (46.6) | 54 (42.2) | 0.55 |
| >30 d | 92 (47.4) | 116 (46.4) | 70 (53.4) | 74 (57.8) | ||
| Time of chemo, n (%)a | ||||||
| ≤60 d | 50 (42.7) | 26 (25.2) | 0.009 | 208 (39.5) | 179 (33.5) | 0.05 |
| >60 d | 67 (57.3) | 77 (74.8) | 318 (60.5) | 355 (66.5) | ||
| Compliance to treatmentb | ||||||
| Appointments cancelled (mean, %) | 17.5 | 16.6 | 0.87 | 19.9 | 19.9 | 0.29 |
Chemo, chemotherapy; PD-L1, programmed death-ligand 1; SEER, Surveillance, Epidemiology, and End Results; UH, University Hospital.
a
Compared with Pearson’s chi-square test.
b
Compared with Kruskal-Wallis test.